Novo Nordisk's CagriSema Data, a Courtroom Rebuff and a Cut Rating All Converge on 4 November
Published on 10/27/2026 at 12:11 | Editorial boerse-global.de
Oddo BHF stripped Novo Nordisk of its Neutral rating on 20 October, moving to Underperform and slashing the price target to DKK 221 from DKK 305. Analyst Florent Cespedes made the call even as the Danish drugmaker was still basking in a run of encouraging product news — a juxtaposition that leaves investors weighing clinical promise against a decidedly more cautious view of the business.
The downgrade landed the same day Novo Nordisk published two post-hoc analyses from its Phase 3 REDEFINE 1 trial, covering 2,309 women with overweight or obesity. Average weight loss under CagriSema came in at 25.0% after 68 weeks, against 3.0% on placebo. Those figures rest on the assumption of continued treatment, and they stem from retrospective analyses rather than a regulatory decision — a caveat that belongs front and centre when reading the numbers.
Subgroup detail added texture. Women who had not yet reached menopause averaged a 26.7% reduction, those going through it 24.8%, and those past it 23.1%. The breakdown sharpens the picture of who responded how, though it offers no explanation for the gap and does nothing to lift the treatment-adherence assumption sitting beneath the headline result.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Mixed Week for the Pipeline
On the product front, the FDA cleared Awiqli — the once-weekly basal insulin — for children aged ten and older with type-2 diabetes, a label expansion that broadens the franchise.
The legal arena delivered the opposite. US District Judge Zahid Quraishi declined Novo's request for a preliminary injunction against Eli Lilly's contested advertising for weight-loss drugs, leaving Lilly free to keep running the spots while the case proceeds. Reuters reported the judge saw at most a negligible market impact from the ads between April and July. Crucially, the ruling settled neither the merits of the misleading-advertising claim nor the underlying suit — it was a procedural blow, not a final legal defeat.
The Numbers That Will Settle the Argument
Novo Nordisk is due to report results for the first nine months of 2026 on 4 November. That date now acts as the hinge for three otherwise separate storylines: efficacy data that come with strings attached, a competitive and legal scrap with Lilly that remains unresolved, and a broker that has turned markedly more bearish. Until the accounts land, none of the recent headlines — however encouraging or discouraging — answers the question of how the business is actually performing.
Ad
Novo Nordisk Stock: New Analysis - 27 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
